Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

NCT02022540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration (AMD)

Interventions

DRUG: PAN-90806 Ophthalmic Solution
DRUG: Lucentis

Sponsor

PanOptica, Inc.